Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Di | Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study | 6 | RTTNews | ||
26.08. | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 1 | Investing.com | ||
06.08. | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
06.08. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.08. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
28.07. | JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data | 2 | Investing.com | ||
08.07. | Upstream Bio startet Phase-2-Studie für COPD-Medikament Verekitug | 1 | Investing.com Deutsch | ||
UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
08.07. | Upstream Bio begins phase 2 COPD trial for verekitug | 1 | Investing.com | ||
08.07. | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | 166 | GlobeNewswire (Europe) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
15.06. | Upstream Bio: Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor | 3 | GlobeNewswire (USA) | ||
05.06. | Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 | 1 | GlobeNewswire (USA) | ||
20.05. | Upstream Bio Appoints Stacy Price As CTO | 1 | RTTNews | ||
20.05. | Upstream Bio names new chief technology officer | 1 | Investing.com | ||
20.05. | Upstream Bio Appoints Stacy Price as Chief Technology Officer | 120 | GlobeNewswire (Europe) | WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
06.05. | Upstream Bio, Inc. reports Q1 results | 3 | Seeking Alpha | ||
06.05. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.04. | Pre-market Movers: Marblegate Acquisition Corp., iCoreConnect, Hyperscale Data, Upstream Bio, InnovAge Holding | 488 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green Marblegate Acquisition Corp. (GATE) is up over 55%... ► Artikel lesen | |
12.03. | Upstream Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics prices upsized $250M stock offering | ||
AVIDITY BIOSCIENCES | 47,230 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
KYMERA THERAPEUTICS | 40,690 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update | Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial... ► Artikel lesen | |
ADMA BIOLOGICS | 17,200 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
ARCELLX | 69,75 | 0,00 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial | ||
TARSUS PHARMACEUTICALS | 58,59 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,840 | 0,00 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
TREVI THERAPEUTICS | 7,270 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
NUVALENT | 76,90 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 44,940 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
RECURSION PHARMACEUTICALS | 4,660 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
CG ONCOLOGY | 27,460 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates | - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ... ► Artikel lesen | |
BEAM THERAPEUTICS | 16,310 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
DYNE THERAPEUTICS | 13,500 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
IMMUNOVANT | 15,070 | 0,00 % | Immunovant, Inc. - 8-K, Current Report |